Clinical trials: Synucleinopathy
Dementia With Lewy Bodies (DLB)
A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies
The purpose of this study is to evaluate the safety and efficacy of E2020 in patients with Dementia with Lewy Bodies (DLB).
- Trial name
- NCT00598650
- Testing
- E2020
- Volunteers
- 160 people
- Sponsor
- Eisai Co., Ltd.
Diabetic Retinopathy, Macular Degeneration
Advancing Understanding of Transportation Options
This Stage II randomized, controlled, longitudinal trial seeks to assess the acceptability, feasibility, and effects of a driving decision aid use among geriatric patients and providers.
- Conditions
- Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa
- Trial name
- AUTO (NCT04141891)
- Testing
- Driving Decision Aid, Older Drivers Website
- Where
- 3 sites in United States
- Volunteers
- 529 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Parkinson's Disease
Cognitive Dysfunction in Parkinson's Disease
This study plans to learn more about the brain function related to thinking problems in individuals with Parkinson's disease.
- Trial name
- NCT02346708
- Testing
- Real TMS
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of Colorado, Denver
Multiple System Atrophy
A Study of TAK-341 in Treatment of Multiple System Atrophy
The main aim is to see how TAK-341 works after 52 weeks in participants with multiple system atrophy as measured by the Unified Multiple System Atrophy Rating Scale Part I (UMSARS).
- Trial name
- NCT05526391
- Testing
- TAK-341
- Where
- 41 sites in United States, Austria and 8 more
- Volunteers
- 158 people
- Sponsor
- Takeda
Parkinson Disease
Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease
The investigators are interested in evaluating the use of oral N-acetylcysteine (NAC) as therapy for Parkinson's Disease (PD) and measuring changes in brain and blood chemistry.
- Trial name
- NCT02212678
- Testing
- N-acetylcysteine capsule
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Minnesota
Parkinson's Disease
Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Apathy in Parkinson's Disease
The purpose of this research study is to attempt to treat apathy in Parkinson's disease (PD) using high-frequency repetitive transcranial magnetic stimulation (rTMS) of the brain and to investigate the patterns of brain…
- Trial name
- ReStore (NCT00955032)
- Testing
- High-Frequency Repetitive Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Florida
Parkinson Disease, Cognitive Impairment
Low Frequency Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease
Prospective trial of low frequency deep brain stimulation of the ventral subthalamic nucleus to improve cognitive performance in patients with advanced Parkinson's disease.
- Trial name
- NCT03204526
- Testing
- deep brain stimulation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, Davis
Symptomatic Neurogenic Orthostatic Hypotension
Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3, multi-center, open-label study to evaluate the safety and tolerability of ampreloxetine in subjects with primary autonomic failures (MSA, PD, and PAF) and symptomatic nOH over 182 weeks.
- Trial name
- OAK (NCT04095793)
- Testing
- ampreloxetine
- Where
- 55 sites in United States, Australia and 16 more
- Volunteers
- 110 people
- Sponsor
- Theravance Biopharma
Parkinson Disease
Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects
To assess the pharmacokinetics of BIA 9-1067 in healthy Japanese subjects
- Trial name
- NCT01520987
- Testing
- BIA 9-1067
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa
The main objective of the study is to explore firstly, then further evaluate and confirm the efficacy between Pramipexole Sustained Release (SR) versus Pramipexole Immediate Release (IR) on nocturnal symptoms (as measured by the…
- Trial name
- NCT03521635
- Testing
- Pramipexole SR, Pramipexole IR
- Where
- 12 sites in China
- Volunteers
- 98 people
- Sponsor
- Boehringer Ingelheim
Parkinson Disease, Movement Disorders
Altropane Dose for Imaging Patients With Suspected Parkinson's Disease
Previous studies showed that a dose of 8 millicuries of Altropane was appropriate for imaging patients with suspected Parkinson's disease. This study determined if a lower dose (5 millicuries) would suffice.
- Trial name
- NCT05636852
- Testing
- Altropane (123I) Injection
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- GE Healthcare
Parkinson Disease, DBS
Utilizing Neural Signatures and Virtual Reality to Advance DBS Programming
The project uses virtual reality technology to recreate situations that cause freezing of gait in individuals with Parkinson's disease.
- Conditions
- Parkinson Disease, DBS, Deep Brain Stimulation, Freezing of Gait
- Trial name
- NCT05103384
- Testing
- Virtual Reality Environment
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- The Cleveland Clinic
Parkinson's Disease
A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations
This is a randomized, double-blind, two treatment, two group, parallel group study. Subjects will be randomized to one of two treatment groups (E2007 or Placebo) in a 3 to 1 ratio and receive treatment for a total of ten weeks…
- Trial name
- NCT00165789
- Testing
- E2007
- Where
- 10 sites in United States
- Volunteers
- 75 people
- Sponsor
- Eisai Inc.
Parkinson Disease
Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide
To investigate the effect of BIA 9-1067 in steady-state conditions on the levodopa pharmacokinetics
- Trial name
- NCT01533116
- Testing
- BIA 9-1067, levodopa/carbidopa, levodopa/benserazide
- Where
- Canada
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease, Parkinsonism
Study of UB-312 in Healthy Participants and Parkinson's Disease Patients
This is a 44-week, randomized, placebo-controlled, double-blind, single-center, phase 1 clinical trial consisting of a dose-escalation Part A study in healthy participants, followed by a Part B in participants with Parkinson's…
- Trial name
- NCT04075318
- Testing
- UB-312
- Where
- Netherlands
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- United Neuroscience Ltd.
Parkinson's Disease
Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment
The purposes of the study are to determine: i. To assess the efficacy of Tigan® (trimethobenzamide) in preventing nausea and vomiting when initiating therapy with Apokyn® (apomorphine) ii.
- Trial name
- NCT00489255
- Testing
- Tigan®
- Where
- 27 sites in United States
- Volunteers
- 117 people
- Sponsor
- Ipsen
Parkinson Disease(PD)
The Stanford Parkinson's Disease Plasma Study
The purpose of this study is to demonstrate that young plasma infusions can be performed safely in patients with Parkinson's Disease (PD).
- Trial name
- SPDP (NCT02968433)
- Testing
- Infusions of young plasma
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Stanford University
Parkinson's Disease
Multi-chip Meta-analysis of Parkinson's Disease for Clinical Validation of Small Samples of Key Genes in Disease
The research team used meta-analytical statistical methods to integrate the results of different research groups on Parkinson's disease, using meta-analysis to find key genes related to the pathogenesis and development of…
- Trial name
- NCT03848455
- Testing
- genetic diagnosis
- Where
- China
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- Zhujiang Hospital
Parkinson's Disease
Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3])
With an appropriate oral dose of Varenicline (VCN) identified from experiments 1 \& 2 of the study (see NCT02933372), the investigators will administer VCN to Parkinson Disease (PD) participants to determine if VCN improves…
- Trial name
- UdallP3E3 (NCT04403399)
- Testing
- Varenicline
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Michigan
Parkinson's Disease
DBS Under General Anesthesia: Comparison To The Standard Technique
There is a growing trend in functional neurosurgery toward direct anatomical targeting for deep brain stimulation (DBS). This study describes a method and reports the initial experience placing DBS electrodes under general…
- Trial name
- NCT01997398
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix